Sleep Apnea Reduced in People Who Took Zepbound, Eli Lilly Reports NYT: Science By: Gina Kolata 17 April 2024 at 06:15 The company reported results of clinical trials involving Zepbound, an obesity drug in the same class as Novo Nordisk’s Wegovy. © Brendan Mcdermid/ReutersIn a study, people with sleep apnea who were randomly assigned to take the weight-loss drug Zepbound had an average of about 30 fewer apnea episodes per hour.
Login
